Get the Stockscreener App
7.06
1.53%
-0.11
Pre-market:
7.06
Cybin Inc stock is traded at $7.06, with a volume of 428.00K.
It is down -1.53% in the last 24 hours and down -5.36% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$7.17
Open:
$7.16
24h Volume:
428.00K
Relative Volume:
1.13
Market Cap:
$166.55M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-33.99
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
-5.23%
1M Performance:
-5.36%
6M Performance:
-25.92%
1Y Performance:
-29.78%
1-Day Range:
$6.99
$7.23
1-Week Range:
$6.99
$7.75
52-Week Range:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.06 | 169.14M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Cybin Posts Q1 2026 Loss of -$0.54 EPS; Market Reacts with Mixed Short-Term Optimism - AInvest
Heatmap Data Shows High Activity in Cybin Inc. SectorRisk Management & Free Weekly Watchlist of Top Performers - newsyoung.net
Cybin Earnings Report (2026 Q1): Negative Net Income, Weak Margins, and Mixed Post-Earnings Market Signals - AInvest
Top Risks to Consider Before Buying Cybin Inc. StockBond Market & Real-Time Market Sentiment Alerts - Newser
Risk adjusted return profile for Cybin Inc. analyzedJuly 2025 Closing Moves & Fast Gain Stock Trading Tips - Newser
Cybin Inc. stock momentum explained2025 Support & Resistance & Consistent Profit Alerts - Newser
Does Cybin Inc. fit your quant trading modelWall Street Watch & Verified Momentum Stock Ideas - Newser
Cybin Inc. recovery potential after sell offInsider Selling & Reliable Breakout Forecasts - Newser
Earnings visualization tools for Cybin Inc.Weekly Stock Summary & Weekly High Potential Alerts - Newser
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin Inc. Reports Q2 2025 Financial Results with Asset Growth - MSN
Real time social sentiment graph for Cybin Inc.2025 Price Targets & Advanced Swing Trade Entry Alerts - Newser
What’s next for Cybin Inc. stock priceQuarterly Earnings Report & Expert Curated Trade Ideas - Newser
Key resistance and support levels for Cybin Inc.Portfolio Update Summary & Safe Capital Investment Plans - Newser
Cybin reports Q1 results - MSN
Is Cybin Inc. stock overvalued or fairly pricedBreakout Watch & Reliable Price Breakout Signals - newsyoung.net
Psychedelic Stock Earnings: atai Life Sciences, Cybin Report Q1 Results - AInvest
Which companies are leading the development of psychedelic wellness products? - AInvest
Cybin Inc. Common Shares (NYSE:CYBN) Stock Quote - FinancialContent
Trend Reversal Possible in Cybin Inc. Charts IndicateWeekly Investment Summary & Fast Entry and Exit Trade Plans - sundaytimes.kr
Psychedelic: atai Life Sciences, Cybin report earnings results - TipRanks
MACD Cross Could Confirm Trend in Cybin Inc.2025 Technical Overview & AI Forecast for Swing Trade Picks - thegnnews.com
Cybin Reports Q1 FY26 Financials, Advances Clinical Programs, and Secures $50M Financing Agreement. - AInvest
Cybin Reports Important Progress on Key Milestones and First Qua - GuruFocus
Cybin Reports Q1 FY26 Financial Results, Advances Key Milestones in Psychedelic Therapies - AInvest
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results - Bluefield Daily Telegraph
Cybin Inc. Amends Convertible Note Agreement with High Trail - TipRanks
Cybin (OTCMKTS:CYBN) Shares Down 2.6% – Should You Sell? - Defense World
What momentum shifts mean for Cybin Inc.Swing Entry Insight With Forecast Accuracy - Newser
Cybin gains Irish Medicines Board approval for major depressive disorder trial - Yahoo Finance
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - BioSpace
Cybin Inc. shares rise 1.13% intraday after receiving approval to initiate EMBRACE trial in Europe. - AInvest
Psychedelic: Cybin receives European approval for EMBRACE study - TipRanks
Cybin receives European approval for EMBRACE trial - TipRanks
Cybin Gets European Approval For EMBRACE Study Of CYB003 For Major Depressive Disorder - Nasdaq
Cybin Secures European Approval for EMBRACE Study in Major Depressive Disorder - TipRanks
Cybin Receives European Approval for EMBRACE, a Multinational Ph - GuruFocus
Cybin receives European approval for phase 3 depression drug trial By Investing.com - Investing.com Nigeria
Cybin receives European approval for phase 3 depression drug trial - Investing.com
Cybin Says Received Approval to Initiate Trial for Major Depressive Disorder in 3 Countries - MarketScreener
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference | CYBN Stock News - GuruFocus
Cybin CEO to Speak at Canaccord Genuity Growth Conference - TipRanks
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference - Business Wire
Cybin Inc. Flashes Rebound Signal in Oversold ConditionAI Driven Buy Alert Trade Blueprint Released - beatles.ru
Technical Heatmap Flags Cybin Inc. for WatchStrong Buy With Technical Confidence Supported - metal.it
Is Cybin Inc. the Top Chart Pick This WeekTrend Analysis for Safer Trades Gains Popularity - metal.it
Using data tools to time your Cybin Inc. exitAI Enhanced Strategy for Portfolio Growth - Newser
What are the latest earnings results for Cybin Inc.Achieve rapid wealth accumulation through smart investing - Jammu Links News
Cybin Inc. Stock Analysis and ForecastFree Market Dynamics Reports - Jammu Links News
How volatile is Cybin Inc. stock compared to the marketCapitalize on emerging investment opportunities - Jammu Links News
What institutional investors are buying Cybin Inc. stockCapitalize on market trends before they peak - Jammu Links News
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Cap:
|
Volume (24h):